Browse the corpus

Luspatercept is an FDA-approved recombinant fusion protein used to manage anemia in patients with β-thalassemia who require regular blood transfusions. This drug is also indicated for adults with very low-to-intermediate risk myelodysplastic syndromes (MDS) who are naive to erythropoiesis-stimulating agents and may need red blood cell transfusions. Luspatercept binds to transforming growth factor-β ligands, reducing SMAD2 and SMAD3 signaling to promote erythroid maturation. This activity reviews the indications, mechanism of action, and contraindications associated with luspatercept. Additionally, the discussion includes proper dosing, administration, and titration based on clinical status. The content also covers warnings related to luspatercept's use and the importance of patient monitoring. Collaboration among interdisciplinary healthcare teams is critical for optimizing treatment safety and improving outcomes for patients with anemia. Objectives: Identify the appropriate indications for luspatercept administration. Evaluate the importance of luspatercept for reducing blood transfusion requirements. Determine the appropriate dosage of luspatercept for a patient with anemia due to myelodysplastic syndrome or β-thalassemia. Identify the importance of improving care coordination among interprofessional team members to enhance care delivery for patients with anemia due to myelodysplastic syndrome and β-thalassemia who are undergoing blood transfusions. Access free multiple choice questions on this topic.

Due to the long half-life of luspatercept, toxicity is not of significant concern. Dosing should be monitored according to hemoglobin levels and should not exceed 1.25 mg/kg for patients with β-thalassemia and 1.75 mg/kg for patients with lower-risk MDS. The adverse effects commonly associated with luspatercept therapy have been discussed above. Discontinue luspatercept administration based on the grade and severity of these reactions.[11]

Managing the administration of luspatercept to patients with anemia from lower-risk myelodysplastic syndrome with ring sideroblasts and β-thalassemia requires an interprofessional team of nurses, laboratory technicians, pharmacists, researchers, and clinicians trained in different specialties. After diagnosis, prompt admission and adherence to therapy are fundamental to the effectiveness of drugs such as luspatercept. Improvement of anemia and reduced blood transfusion requirements are critical factors for favorable treatment outcomes. Common obstacles to success include limited clinical trials for treating anemia resulting from other conditions. The emphasis on monitoring hemoglobin and transfusion requirements is critical. Clinicians must communicate openly, educate the patient, and monitor labs and treatment outcomes. The clinical pharmacist plays a vital role in medication consultation, verifying dosing parameters, and overseeing administration. During follow-up visits, the nursing team must verify hemoglobin levels by reviewing symptoms of anemia and lab results. Failure to comply with all aspects of administration and monitoring may result in detrimental effects on the patient's health. The interprofessional team must communicate, support, and monitor the patient to ensure the best chance for therapeutic success with minimal adverse events.